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A2 - second virial coefficient 
ACF – autocorrelation function 
AFSTD - protein-additive saturation transfer difference amplification factors from NMR 
D - mutual diffusion coefficient from DLS 
DLS - dynamic light scattering 
Dmax – maximum dimension from SAXS 
FI350/FI330 – intrinsic protein fluorescence intensity ratio 350nm/330nm 
IP1 - inflection point of the first thermal unfolding (at a lower temperature)  
IP2 - inflection point of the second thermal unfolding (at a higher temperature)  
kD - interaction parameter  
nanoDSF® - fluorimetric method based on intrinsic protein fluorescence  
P(r) – pair distance distribution function 
ReFOLD – isothermal unfolding/refolding assay to assess protein aggregation 
Rg – radius of gyration from SAXS 
Rh - apparent protein hydrodynamic radius from DLS 
RMY - relative monomer yield after refolding 
SAXS – small-angle X-ray scattering  
SEC - size exclusion chromatography  
SLS – static light scattering 
STD-NMR – saturation transfer difference nuclear magnetic resonance 
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ABSTRACT 
Understanding the effects of additives on therapeutic protein stability is of paramount 
importance for obtaining stable formulations. In this work, we apply several high- and medium-
throughput methods to study the physical stability of a model monoclonal antibody at pH 5.0 and 6.5 in 
the presence of sucrose, arginine hydrochloride and arginine glutamate. In low ionic strength buffer, 
the addition of salts reduces the antibody colloidal and thermal stability, attributed to screening of 
electrostatic interactions. The presence of glutamate ion in the arginine salt partially reduces the 
damaging effect of ionic strength increase. The addition of 280 mM sucrose shifts the thermal protein 
unfolding to a higher temperature. Arginine salts in the used concentration reduce the relative 
monomer yield after refolding from urea, while sucrose has a favorable effect on antibody refolding. In 
addition, we show 12-month long-term stability data and observe correlations between thermal protein 
stability, relative monomer yield after refolding and monomer loss during storage.  The monomer loss 
during storage is related to protein aggregation and formation of subvisible particles in some of the 
formulations. This study shows that the effect of commonly used additives on the long-term antibody 
physical stability can be predicted using orthogonal biophysical measurements. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
One fundamental aim during the development of therapeutic proteins is finding formulations 
that provide sufficient protein stability during long-term storage. Some critical variables of these 
formulations are solution pH, ionic strength, and the presence of additives. The additives usually 
belong to the group of sugars, polyols, amino acids, or surfactants1,2. Among these, sucrose is the 
most frequently used in marketed therapeutic protein formulations1. From the amino acids, arginine is 
of considerable interest, as in some cases it can suppress protein aggregation or reduce the viscosity 
of highly concentrated protein solutions3,4. Also, the use of different arginine salts is a topic of intense 
research since the arginine counterion can determine the effect on protein stability4–7.  
Sucrose and arginine salts can affect the thermal protein unfolding and aggregation differently 
depending on the protein molecule. The presence of other buffer components, such as NaCl, which 
modify the ionic strength of the solution, can also influence the direction and the magnitude in which 
arginine salts impact protein physical stability5,8–11. Especially arginine can have complex effects on 
the protein unfolding, aggregate formation and aggregate growth, depending on the conditions and the 
nature of its counter-ion7,12. The concentration of the additive is also essential but limited by the target 
osmolality of the formulation that typically should be close to physiological13. Many of the studies with 
sucrose and arginine salts observe effects on protein stability that depend on the additive 
concentration5,8,9,11. Often, 0.5-1 M of sucrose or arginine hydrochloride (ArgHCl) has a beneficial 
impact on protein stability8,14–17, whereas for arginine glutamate (ArgGlu) the optimal working 
concentration is typically much lower, 50-200 mM5,6,18. High concentrations of additives make the 
solutions hypertonic and thus unsuitable for therapeutic protein formulations that will be injected 
undiluted in patients. Therefore, it is essential to study the effect of additives on protein stability in 
concentrations realistic for medicinal products. Just as importantly, published work on the impact of 
additives on protein stability is often not supported by long-term stability data to confirm that an 
additive will have a stabilizing or destabilizing effect during storage at temperatures relevant for 
therapeutic proteins. 
 The effects of additives on protein physical stability can be studied with various biophysical 
methods that require different sample volume and analytical effort. There are different classifications of 
these methods, some of which are based on throughput19. However, there are not always well-defined 
borders that would classify a method as high- or medium-throughput. In general, a higher throughput 
is related to lower sample volume, shorter measurement time and a high potential for method 
automation. Based on these criteria, in our work, we would like to define as high-throughput methods 
all methods that require less than 100 µL sample, less than a day to complete the measurements for 
many samples and that can be automated. This includes nanoDSF® and DLS performed on samples 
in multi-well plates. As medium-throughput methods, we define techniques that require larger sample 
volume, up to 1 mL, longer time and higher analytical effort, and less potential for automation. Such 
techniques in the presented work are SAXS and NMR. The ReFOLD assay, which we also employ, 
falls in between high- and medium-throughput since it requires small sample volumes, is performed in 
deep multi-well plates, could be automated, but requires a few days to complete in its current set-up. 
In this work, we apply the high- and medium-throughput methods mentioned above to study 
the effect of three additives, 280 mM sucrose, 140 mM ArgHCl, and 70 mM ArgGlu on the physical 
stability of a model monoclonal antibody at pH 5.0 and 6.5. We focus on the impact of the additives on 
the colloidal protein stability and the protein aggregation during refolding from urea. Finally, we 
perform long-term stability studies for 12 months at 4 °C and 25 °C to investigate if the quick 
biophysical characterization can foresee the effects of the additives on the protein long-term storage 
stability. 
 
MATERIALS AND METHODS 
Monoclonal antibodies and chemicals 
The monoclonal antibody PPI13 used in this work is a human IgG1κ with a molecular mass of 
148.9 kDa and an isoelectric point around 9. In the near future, the primary protein sequence and 
additional information about PPI13 will be available in an online database (https://pippi-
data.kemi.dtu.dk/). PPI13 was supplied in surfactant-free bulk solution with protein concentration 43 
g/L. Size exclusion chromatography was used to check the purity of PPI13 in bulk and showed ˃97 % 
monomer relative monomer content. The bulk buffer was exchanged to 10 mM histidine/histidine 
hydrochloride with pH 5.0, 5.75 and 6.5 at 25 °C using extensive dialysis as described earlier20. The 
absorption of PPI13 at 280 nm was measured with a Nanodrop 2000 UV spectrophotometer (Thermo 
Fisher Scientific, Wilmington, DE) and the protein concentration was calculated using the protein 
extinction coefficient. Stock solutions of the additives - sucrose, ArgHCl, ArgGlu, guanidinium 
hydrochloride (GuHCl) and NaCl - were prepared in the respective histidine buffer and spiked to the 
dialyzed protein solution. All chemicals were high purity grade and were purchased from Sigma Aldrich 
(Steinheim, Germany), VWR International (Darmstadt, Germany) or Fisher Scientific (Schwerte, 
Germany). Ultrapure water from an arium® system (Sartorius Lab Instruments GmbH, Goettingen, 
Germany) was used to prepare all solutions.  
Long-term stability study 
PPI13 samples with protein concentration of 5 g/L in the respective buffer (or buffer plus 
additive) were sterile filtered with a 0.22 µm cellulose acetate filter, aseptically filled into sterilized 
DIN2R glass type I vials (MGlass AG, Germany), crimped with FluroTec® coated rubber chlorobutyl 
stoppers (West Pharmaceutical Services, USA), and stored at 4 °C and 25 °C for the desired time. 
Three different vials were used for the analysis of each condition and time. 
Dynamic light scattering (DLS) 
Before DLS measurements, all samples were centrifuged at 10,000g for 10 minutes. Next,  
10 µL of PPI13 solution with 5 g/L protein concentration, unless otherwise stated, were filled in a 1536 
microwell plate (Aurora, Whitefish, USA). The plate was centrifuged at 2200 rpm for 2 minutes using a 
Heraeus Megafuge 40 centrifuge equipped with an M-20 well plate rotor (Thermo Fisher Scientific, 
Wilmington, USA). Each well was subsequently sealed with 5 µL silicon oil and the plate was 
centrifuged again. The samples were then measured on a DynaPro plate reader III (Wyatt Technology, 
Santa Barbara, USA) using 3 acquisitions of 3 seconds during a linear temperature ramp of 0.1 °C/min 
from 25 to 85 °C. The Dynamics V7.8 software was used to visualize the autocorrelation functions 
(ACF) and to apply cumulant analysis giving the mutual diffusion coefficient (D) and the polydispersity 
index (PDI). The apparent protein hydrodynamic radius (Rh) was calculated using the Stokes-Einstein 
equation from the D and the sample viscosity. The sample viscosity was measured with a falling ball 
viscometer AMVn (Anton Paar GmbH, Ostfildern-Scharnhausen, Germany). The aggregation onset 
temperature (Tagg) was determined using the onset fit function of the Dynamics V7.8 software from the 
Rh increase during heating. To derive the interaction parameter kD, PPI13 samples with different 
protein concentration (see the Results section) were filled in 1536 microwell plates as described 
above. The samples were then measured at 25 °C with 10 acquisitions of 5 seconds. The mutual 
diffusion coefficient D was calculated as described above and the following equation was used to 
extract kD: 
D=D0(1+kDc) 
where D0 is the diffusion coefficient at infinite dilution and c is the protein concentration. All DLS 
measurements were performed in triplicates. 
High-throughput Fluorimetric Analysis of Thermal Protein Unfolding with nanoDSF® 
The thermal unfolding of 5 g/L PPI13 in different formulations was studied with nanoDSF®21,22. 
The samples were filled in standard glass capillaries, the capillaries were sealed and placed in a 
Prometheus® NT.48 (NanoTemper Technologies, Munich, Germany). The device was used to linearly 
change the sample temperature from 25 to 100 °C with a ramp of 0.1 °C/min. During the temperature 
increase, the intrinsic protein fluorescence intensity at 330 nm and 350 nm was measured after 
excitation at 280 nm (±10 nm). Simultaneously, the back-reflection intensity of a light beam that 
passes through the capillary was measured to detect protein aggregation/precipitation. The scattering 
signal was normalized to the baseline signal to obtain a value called “Excess Scattering”. The 
fluorescence intensity ratio (FI350/FI330) was plotted versus temperature, and the first (IP1) and 
second (IP2) inflection points of the protein thermal unfolding curve were determined from the maxima 
of the first derivative using the PR.ThermControl V2.1 software (NanoTemper Technologies, Munich, 
Germany). The protein thermal unfolding curves and inflection points measured with nanoDSF 
typically agree well with the unfolding curves and melting temperatures obtained with techniques like 
differential scanning calorimetry and circular dichroism23,24. 
Isothermal unfolding and refolding with urea (ReFOLD assay) 
The assay was performed as described earlier20. Briefly, 50 µL of 5 g/L PPI13 solution in the 
respective buffer (or buffer plus additive) were filled in Pierce™ microdialysis devices  
(3.5 kDa MWCO). The samples were dialyzed in a deep well-plate against 1.5 mL of 9 M urea 
dissolved in the respective formulation buffer (or buffer plus additive). The urea solution was changed 
after 4 and 8 hours and the dialysis continued for 24 hours in total. Next, the PPI13 samples in 9 M 
urea were dialyzed using the same procedure against 1.5 mL of the respective urea-free formulation 
buffer (or buffer plus additive). During dialysis, the deep well plate was agitated at 700 rpm with a 
Thermomixer Comfort (Eppendorf AG, Hamburg, Germany). Subsequently, the samples were 
collected from the dialysis devices, each sample was weighed on a microbalance and the respective 
urea-free formulation buffer was added to a final weight of 250 mg. Finally, the samples were 
centrifuged at 10,000g for 10 minutes, and the supernatant was used for further measurements. 
Size exclusion chromatography (SEC) 
A Dionex Summit 2 system equipped with a UVD170U UV/Vis detector (Thermo Fisher, 
Dreieich, Germany) was used to inject PPI13 samples on a TSKgel G3000SWxl, 7.8x300 mm, 5 µm 
column (Tosoh Bioscience, Tokyo, Japan). The mobile phase with pH 7.0 consisted of 100 mM 
potassium phosphate, 200 mM sodium chloride and 0.05 % w/v sodium azide. The elution of the 
samples was detected at 280 nm. The chromatograms were collected and integrated with Chromeleon 
V6.8 (Thermo Fisher, Dreieich, Germany). The relative monomer yield (RMY) of the protein after 
isothermal unfolding/refolding in urea was calculated after dividing the area of the monomer peak of 
the refolded sample by the area of the monomer peak of the sample before unfolding/refolding20. The 
soluble protein yield after refolding was calculated by dividing the area of all protein peaks detected 
with SEC after refolding by the area of all protein peaks before refolding. The value is then multiplied 
by 100 to obtain the soluble protein yield as a percentage. The relative area of aggregates and the 
monomer recovery of PPI13 during long-term storage were calculated as earlier described20. Briefly, 
the area of the monomer peak after storage was divided by the area of the monomer peak measured 
at the beginning of the stability study and multiplied by 100. Thus, the monomer recovery will account 
for monomer loss during storage both due to the formation of small soluble aggregate and subvisible 
particles. The relative area of aggregates in the SEC chromatogram was calculated as the area of the 
aggregate peaks was divided by the total area of all protein peaks in the chromatogram and multiplied 
by 100. Therefore, the relative area of aggregates represents the small aggregates as a fraction of the 
soluble protein that is observed during elution in the SEC experiment. The relative area of fragments 
was calculated in an analogical way to the relative area of the aggregates. Finally, the loss of soluble 
protein was calculated from the change in the summed area of all protein peaks (i.e. aggregates, 
monomer and fragments) after storage. 
Flow imaging microscopy  
The subvisible particles formed during long-term storage of PPI13 were measured with a 
FlowCAM® 8100 (Fluid Imaging Technologies, Inc., Scarborough, ME, USA) equipped with a 10x 
magnification cell (81 µm x 700 µm). Particle images were obtained using 150 µL sample volume, a 
flow rate of 0.15 mL/min, an auto image frame rate of 29 frames/second and a sampling time of 74 
seconds. The particle identification settings were 3 µm distance to the nearest neighbor, particle 
segmentation thresholds of 13 and 10 for the dark and light pixels respectively. The particle size 
reported represents the equivalent spherical diameter (ESD). The data was collected and processed 
with the VisualSpreadsheet® 4.7.6 software. 
Small-angle X-ray scattering (SAXS) 
Data collection was performed at the P12 beamline at the Petra III storage ring (DESY, 
Hamburg DE)25 (see Table S1 in the Supplementary data for experimental details). The radius of 
gyration (Rg) and the maximum dimension (Dmax) of PPI13 were derived from the experimental data 
with the data analysis program PRIMUSqt from the ATSAS software suite26,27. The protein molecular 
mass (Mm) was calculated from the Porod volume (Mm = Porod volume x 1.7), because this 
determination does not depend on absolute scaling or protein concentration. 
Nuclear magnetic resonance (NMR) 
NMR samples were prepared by the addition of 2H2O to a final concentration of 5 % v/v in 
each protein formulation and transferred to 5 mm NMR tubes (Wilmad). Protein concentration was 50 
µM. Titration experiments were performed by reconstitution of pre-measured freeze-dried aliquots of 
additive with the protein sample. All NMR experiments were acquired at 25 °C on a Bruker 800 MHz 
Avance III spectrometer equipped with 5 mm TCI cryoprobe and temperature control unit. At each 
point of the titration, a saturation transfer difference (STD) spectrum was acquired using a standard 
Bruker stddiffesgp.3 pulse sequence with 20 ms spin-lock filter to eliminate protein signals. The on- 
and off-resonance saturation frequencies were 0.175 ppm and 20 ppm, respectively, with saturation 
time of 2.0 s. STD spectra were obtained by subtraction of on-resonance spectrum from the off-
resonance spectrum. STD-amplification factors were calculated as described elsewhere28.  Peak 
assignment and representative examples of the STD-NMR spectra can be found in the Supplementary 
data (Fig S1). 
 
RESULTS AND DISCUSSION 
Effect of pH, sucrose and arginine salts on the thermal unfolding and aggregation of PPI13 
In the buffer chosen for the study, at low ionic strength, PPI13 shows two unfolding transitions 
detected by the change in the intrinsic protein fluorescence ratio (Fig 1a). These transitions 
correspond well to the temperatures of circular dichroism changes in the near-UV protein spectra (Fig 
S2). Increasing pH from 5.0 to 5.75 and then further to 6.5 shifts the inflection point of the first 
unfolding transition to a higher temperature, while the effect on the second inflection point is minimal. 
In buffer with pH 5.0, the protein aggregation onset temperature measured with dynamic light 
scattering is around 78 °C and the Rh does not become larger than 7-8 nm up to 85 °C (Fig 1b). 
Correspondingly, no formation of large aggregates is detected with nanoDSF® up to 100 °C (Fig 1c). 
The reason for this is that the aggregation detection method of nanoDSF® can detect only larger 
particles (see Ref.23), which were not present in the solution as evident from the DLS measurements. 
At pH 6.5, the Tagg from DLS is slightly lower (76.7 °C), and the sample Rh and excess scattering 
rapidly increase which indicates the formation of large aggregates and precipitation (Figs 1b and 1c). 
At pH 5.75, the measured parameters for PPI13 with nanoDSF and DLS fall in between the values 
measured at pH 5.0 and pH 6.5. Such pH dependence of thermal unfolding and aggregation is already 
reported for several other monoclonal antibodies21,29–31. We then focused on the effect of several 
additives on the stability of PPI13 at pH 5.0 and pH 6.5 since the protein behaves differently in these 
conditions concerning its thermal unfolding and aggregation.  
The addition of 280 mM sucrose shifts the inflection points of the unfolding transitions and the 
aggregation onset to a slightly higher temperature independent of pH and without affecting the 
aggregate growth (Figs 1d and 1g) (for values see Table 1). The stabilization effect of sucrose is 
known and can be explained by preferential exclusion30–34.  
Contrary to sucrose, the addition of 140 mM ArgHCl at pH 5.0 shifts the protein aggregation 
onset and the inflection points of both unfolding transitions to lower temperatures (Fig 1d) (Table 1).  
ArgGlu has a more complex effect on the stability of PPI13 at pH 5.0, reducing the aggregation onset 
temperature, but in most cases slightly increasing the temperature of both thermal unfolding inflection 
points (Table 1). The addition of arginine salts causes the formation of larger protein aggregates at pH 
5.0 (Figs 1e and 1f). At pH 6.5, 140 mM ArgHCl and 70 mM ArgGlu affect the Tagg, IP1 and IP2 of 
PPI13 in a similar direction but with a smaller magnitude compared to pH 5.0 (Table 1). The early 
onset of protein aggregation induced by ArgHCl at pH 5.0 (indicated by an arrow in Fig 1e) is not 
observed at pH 6.5. As the starting ionic strength of the buffers used here is very low, the addition of 
ionic compounds, such as arginine salts, is expected to screen the electrostatic repulsion between 
PPI13 molecules bearing overall positive charge at pH 5.0 and 6.5, and partially screen intra-
molecular Coulomb interactions, affecting both colloidal and thermal stability.  
Our findings agree well with published data about the effect of ArgHCl on the thermal 
unfolding of some proteins9,35,36. Here, we should note that the pH of the histidine buffer will change 
slightly during heating, but this pH change is the same regardless of the additive. Therefore, thermal 
denaturation techniques can still be used as a quick check to see whether an additive affects the 
thermal stability of a protein or not. The unfavourable effect of arginine salts on the aggregation onset 
temperature of PPI13 under low ionic strength conditions encouraged us to investigate further the 
reasons for reduced colloidal stability in more detail using isothermal techniques that are more suitable 
for studies on histidine-based formulations. 
Effects of sucrose and arginine salts on the colloidal stability of PPI13 
Dynamic light scattering was used to study the effect of the additives on the colloidal stability 
of PPI13. In 10 mM histidine buffer with pH 5.0 and pH 6.5, at low ionic strength, the mutual diffusion 
coefficient of the protein increases with an increase in protein concentration (Fig 2). The addition of 
280 mM sucrose does not change the sign of this concentration dependence. However, when 140 mM 
ArgHCl or 70 mM ArgGlu is added, the mutual diffusion coefficient of the protein decreases with 
increasing protein concentration (Fig 2). This effect can be explained by the increase in ionic strength 
upon addition of the arginine salts, which leads to the screening of the electrostatic repulsion between 
the protein molecules37. We also used the data in Fig 2 to derive the interaction parameter kD of PPI13 
in these formulations (Table 1). Here, we would like to make a note that the kD values obtained at pH 
6.5 without arginine salts could be overestimated due to the low ionic strength of the solution38, but 
their sign should not be affected. To confirm the observations in Fig. 2, we used multi-well plate-based 
static light scattering method to measure second virial coefficients A2 of PPI13 in the presence of the 
additives and found good agreement between kD and A2 (Figure S3) that is already reported earlier for 
other antibodies39.  
Based on the kD and A2 data, we could confirm that the addition of both arginine salts reduces 
the repulsive protein interactions, thus reducing the colloidal stability of PPI13 which corresponds well 
with the lower aggregation onset temperatures (Table 1) and the larger aggregate growth at pH 5.0 
(Figs 1e and 1f). This effect can be attributed to an increase in the ionic strength of the solution upon 
addition of these salts. Sucrose (280 mM), which does not change the ionic strength, has a much 
smaller effect on the kD and A2 of PPI13 compared to the arginine salts (Tables 1 and S2). 
Effects of pH, sucrose and arginine salts on PPI13 detected with SAXS 
The P(r) functions of PPI13 have a double peak in all conditions tested, which is characteristic 
for multidomain proteins like monoclonal antibodies (Figs 3a and 3b). The P(r) function of the protein 
in 10 mM histidine with pH 5.0 and 6.5 without additives exhibits only a slightly different peak shape, 
meaning that the difference in pH between these two conditions probably has a minor effect on the 
conformation/structure of PPI13 (Figs 3a and 3b). Such structural differences were not detectable with 
near-UV circular dichroism (data not shown). However, at pH 5.0 the first thermal unfolding transition 
of PPI13 is at significantly lower temperatures compared to pH 6.5, indicating lower conformational 
stability (Fig 1a). Increasing the PPI13 concentration from approximately 2 g/L to 7 g/L at pH 5.0 leads 
to a small decrease in Dmax from 15.2 to 14.0 nm and does not change the protein molecular mass 
which is in good agreement with the expected value for the monomeric protein (Figs 3c and 3e). When 
the PPI13 concentration is increased from approximately 2 g/L to 7 g/L in 10 mM histidine buffer with 
pH 6.5 without additives, the Dmax increases slightly from 15.5 to 16.4 nm, and the protein molecular 
mass also increases from 155 to 172 kDa (Figs 3d and 3f). Such an increase could be due to the 
presence of oligomers appearing at higher concentrations. Further support for this hypothesis is that 
dynamic and static light scattering indicated the formation of larger species at protein concentrations 
above 10 g/L. Here, we should note that between 1 and 10 g/L, the mutual diffusion coefficient of 
PPI13 from DLS changed linearly with protein concentration (Fig 2). Even if we assume that the 
change in the diffusion coefficient is due to mixed effects of transient interactions and weak oligomer 
formation, we will still be correct in our earlier statements that a more pronounced decrease in D with 
increasing protein concentration indicates lower colloidal stability. In addition to these observations, 
PPI13 showed pH-, buffer- and additive-dependent solubility problems when we tried to concentrate 
the protein above 20 g/L (data not shown). Such solubility problems occurred, for example, when we 
increased the ionic strength of the solution by addition of NaCl, or when we tried to dialyze the protein 
in other buffers like citrate or phosphate. The addition of 280 mM sucrose has minor effects on the P(r) 
function, Dmax and the molecular mass of PPI13 compared to no additive (Fig 3). Both arginine salts 
induce changes in the shape of the peak in the P(r) function (Figs 3a and 3b). Moreover, the Dmax and 
the Mm of PPI13 in the presence of arginine salts is higher comparing to the one without additives 
(Figs 3c, 3d, 3e and 3f), which points to the formation of protein oligomers. Contrary to the samples 
with no additive and with sucrose, the P(r) function of PPI13 in the presence of ArgHCl and ArgGlu 
has a characteristic tail, which is also an indication of the presence of oligomers (Figs 3a and 3b). The 
small-angle X-ray scattering curves of all measured PPI13 samples can be found in the 
Supplementary data (Figs S4 and S5), and the corresponding parameters from the analysis are 
summarized in Table S3. 
Arginine salts reduce the colloidal and thermal stability of PPI13 due to an increase in ionic strength 
Looking for a better understanding of how the additives affect the stability of PPI13, we 
assessed the IP1, IP2, Tagg, kD and A2 parameters of PPI13 in GuHCl and NaCl solutions having the 
same molar concentration as the arginine salts used above (Table S2). Both 140 mM GuHCl and 140 
mM NaCl cause PPI13 unfolding and aggregation at a lower temperature in a similar way to ArgHCl 
(Table S2).  These results indicate that the negative impact of ArgHCl on PPI13 is due to an increase 
in ionic strength and subsequent reduction in the colloidal protein stability, rather than the Arg cation 
itself. Interestingly, 70 mM ArgGlu has a significantly less negative impact on the thermal protein 
unfolding and aggregation compared to 70 mM GuHCl or 70 mM NaCl, with the latter being the most 
damaging for both the colloidal and thermal stabilities (Table S2). We conclude that the increase in 
ionic strength itself significantly reduces the physical stability of PPI13, however, the nature of ions in 
ArgGlu can partially offset this effect, and more so than in ArgHCl. This indicates once again the 
advantage of ArgGlu over ArgHCl. As a control, we measured the osmolarity of the solutions, as a 
proxy for the ionic strength. The osmolarity of the formulations with all salts tested corresponds to the 
expected osmolarity of strong binary electrolytes (Table S4), indicating that the ionic strength of the 
formulations including salts with the same molar concentration will be similar. Small differences from 
the expected osmolarity were observed in some cases, e.g. for arginine hydrochloride and guanidine 
hydrochloride. These differences could be due to the way of interaction of the additives with the 
protein40.  
Interaction of additives with PPI13 
We used saturation transfer difference NMR (STD-NMR) spectroscopy to assess the 
interactions of sucrose and arginine salts with PPI13 at pH 5.0 and 6.5. Saturation difference 
amplification factors (AFSTD), which show increased value if the ligand spends a considerable amount 
of time in the proximity to the protein, were calculated and plotted as a function of additive 
concentration. The concentration dependencies of AFSTD of each additive, at the two pH values, are 
very similar (Fig 4). Saturation of AFSTD values as additive concentration was increased is not 
observed in any of the tested conditions, indicating that interactions of additives with PPI13 are 
generally weak and transient, with an estimated dissociation constant greater than 100 mM. However, 
we can see a difference in the interactions of ArgHCl and ArgGlu compared to sucrose. All AFSTD 
values for different sucrose protons reach approximately the same value, indicating that sucrose does 
not have a preferential orientation when it interacts with PPI-13, suggesting that the interaction is 
isotropic and unspecific. On per-molar concentration basis, the values of AFSTD for sucrose were also 
much weaker than some of the values displayed by ArgHCl or ArgGlu protons (Fig 4). The AFSTD 
values for different protons of ArgHCl and ArgGlu were much more varied, implying more anisotropic 
interactions and suggesting that these additives have clear preferred orientations for the transient 
binding. In both cases, Arg interacts with PPI13 through the side chain, as evident by increasing AFSTD 
along the sidechain, towards the positively charged end. In the case of ArgGlu, glutamate binds to 
PPI13 as well, through the negatively charged side chain. Together these data indicate preferential 
binding of arginine salts to PPI13, and ArgGlu producing stronger saturation transfer effect than 
ArgHCl, which suggests that in the presence of Glu arginine probably spends more time in bound 
state, then in the presence of Cl-. This fits with the earlier suggestions regarding the nature of 
synergistic effect in Arg-Glu mixtures.18 Transient binding of Arg and Glu with PPI13 is likely to 
neutralize the surface charges on the protein molecule, screening the overall repulsive interactions in 
this case, and decreasing its colloidal stability. This further supports the earlier observations that 
arginine salts reduce the aggregation onset temperatures, the interaction parameter kD, and the 
second virial coefficient A2, when added to PPI13 in 10 mM histidine buffer. The saturation transfer 
data is also consistent with the preferential exclusion of sucrose as a dominant mechanism for PPI13 
stabilization.  
 
Effect of additives on the aggregation during refolding of PPI13 
We recently presented an unfolding/refolding assay, named ReFOLD, that can be used to 
assess the aggregation of urea-induced partially unfolded protein species20. We applied this assay to 
study whether the additives tested here suppress the aggregation of the partially unfolded protein at 
pH 5.0 and pH 6.5. The 9 M concentration of urea was selected since it causes significant 
perturbations in the protein structure as shown by the change in the circular dichroism protein spectra 
(Fig S6). Also, 280 mM sucrose, 140 mM ArgHCl and 70 mM ArgGlu can be dissolved in this urea 
concentration.  
After isothermal unfolding and refolding of PPI13, there is a significant reduction in the 
monomer peak detected by size exclusion chromatography (Fig 5a). This decrease is due to protein 
aggregation during refolding from urea, which leads both to the formation of smaller aggregates that 
can be detected with SEC and to the formation or larger aggregates that are filtered by the SEC 
column.  We reported earlier similar observations for two other monoclonal antibodies20. We then 
calculated the relative monomer yield (RMY) and soluble protein yield after refolding and observed 
that these values were lowest when the refolding was performed at pH 5.0 in the presence of 140 mM 
ArgHCl or 70 mM ArgGlu (Fig 5b). This corresponds well with the detrimental effect of these salts on 
the colloidal stability of PPI13 when added to the 10 mM histidine buffer that has low ionic strength. 
The addition of 280 mM sucrose results in higher RMY and soluble protein yield at both pH 5.0 and pH 
6.5 which agrees with the stabilizing effect of this sugar during thermal denaturation of PPI13 (Figs 5b 
and 5c). In addition, the mean values of RMY are slightly higher at pH 6.5 compared to their 
counterparts at pH 5.0. That concurs with the other stability-indicating parameters measured earlier at 
these pH values (Table 1). The soluble protein yield correlates well with the RMY, which indicates that 
most of the PPI13 monomer is lost after refolding due to the formation of larger aggregates that are 
too large to be detected with the SEC method. The near-UV CD spectra of the refolded PPI13 
resembled the spectra of the native PPI13 in all formulation that we tested (Fig S6). 
The results that arginine salts reduce the relative monomer yield after refolding from urea 
might appear surprising at first since arginine is often used at high concentrations (i.e. 0.5-1.0 M) to 
suppress aggregation during refolding41. However, the formulations of PPI13 present an interesting 
case. As we showed earlier, PPI13 has high colloidal stability at low ionic strength in 10 mM histidine 
with pH 5.0 or pH 6.5. The addition of salts in concentration 70-140 mM negatively affects the colloidal 
protein stability and reduces the repulsive protein-protein interactions as shown by the reduction in the 
interaction parameter kD and the aggregation onset temperature (Tables 1 and S2). Published work 
shows that the protein-protein interactions are directly linked to the aggregation during refolding of 
some proteins17,42. This reveals that the effects of additives on the protein colloidal stability should be 
carefully considered from case to case, taking into account the solution conditions, to have a better 
understanding why specific concentrations of some additives promote protein aggregation during 
heating and refolding from denaturants. 
Effect of sucrose and arginine salts on the aggregation of PPI13 during long-term storage  
The stability of PPI13 during long-term storage at 4 °C and 25 °C was assessed with size 
exclusion chromatography and flow imaging microscopy. PPI13 presents a case in which the amount 
of soluble aggregates detected by SEC remained constant or decreased marginally during storage 
(Fig S7). These aggregates were present in the bulk solution, which has about nine-fold higher protein 
concentration than the 5 g/L we used in our stability studies. The observation with SEC that the 
amount of soluble aggregates in the samples does not increase after storage were confirmed with 
dynamic light scattering (data not shown). Future work can focus on the aggregation mechanism and 
type of aggregates formed by PPI13, and how the aggregation depends on protein concentration. 
A decrease in the monomer recovery of PPI13 was observed after storage which indicated a 
loss of soluble protein probably due to the formation of larger aggregates that are filtered out by the 
SEC column (Fig 6). Further support for this hypothesis is that we also observed a loss of soluble 
protein that correlated well with the decrease in the monomer recovery (Fig 6). In general, the 
decrease in monomer recovery was more pronounced at pH 5.0 compared to pH 6.5, and during 
storage at 25 °C compared to 4 °C. The formulations including 280 mM sucrose showed the highest 
recovery at both storage temperatures and both at pH 5.0 and pH 6.5. Interestingly, the formulations 
with 70 mM ArgGlu had monomer recoveries close to 100 % at pH 6.5 but not at pH 5.0. 
We also observed fragmentation and formation of fragments in some of the samples. All 
conditions contained approximately 0.1 % relative fragment content at the beginning of the stability 
study. After 12-month storage at 4 °C, this level increased to 0.2 % in all samples tested, regardless of 
pH and additives. After storage at 25 °C for 12 months, the relative fragment area increased from 0.1 
% to approximately 1.2 % in all conditions with pH 6.5, without influence from the additives. When the 
protein was stored at pH 5.0 without additive or with 280 mM sucrose, the relative area of fragments 
was 1.5 % after 12 months at 25 °C. However, when the protein was stored in the presence of 
arginine salts at pH 5.0 we observed a slightly higher relative amount of fragments of approximately 2 
%. 
The monomer loss of PPI13 in some of the samples is a result of the formation of larger 
aggregates detected as subvisible particles with flow imaging microscopy (Fig 7).  At pH 5.0, the two 
arginine salts induced the formation of the largest number of particles in all three size ranges. 280 mM 
sucrose reduced the number of particles formed at pH 5.0 compared to no additive. These results 
concur well with the monomer recovery in Fig 6a. At pH 6.5 the particle counts were very low 
independent of the presence of additives. The samples stored at 4 °C showed very low particle 
numbers at both pH 5.0 and pH 6.5, and no clear difference between effect of different additives could 
be observed (Fig S8). The loss of monomer in samples where no subvisible particles were detected 
remains an open question. We assume that this monomer loss is either due to the formation of 
particles with size in the analytical gap between flow imaging microscopy and SEC (i.e. in the 
submicrometric range).  
 
Correlation between stability-indicating parameters and long-term stability 
To conclude the study, we looked for correlations between the different biophysical 
parameters measured and the monomer recovery and particle numbers after long-term storage at 25 
°C. The rankings from the first thermal unfolding inflection point and the relative monomer yield after 
refolding from urea showed the strongest correlation with long-term stability data (Fig S9). In general, 
some of the correlations (Fig S9 – A, B, C, D, E) are weak due to the low particle numbers and small 
differences between most of the formulations. This causes the points to cluster in a narrow range. The 
least stable formulations during long-term storage were the two formulations where the protein unfolds 
at lower temperature and has the lowest aggregation onset temperature, the lowest relative monomer 
yield after refolding from urea, and a negative interaction parameter kD. Sucrose in concentration of 
280 mM increases the temperature of thermal unfolding and the relative monomer yield after refolding 
from urea at pH 5.0. This corresponds well to the stabilizing effect of sucrose observed during storage 
compared to no additive. Many of the formulations, e.g. at pH 6.5, exhibit high monomer recovery and 
low particle numbers independent of the presence of an additive. It remains an open question, 
whether a difference between these formulations would be seen after longer storage time, i.e. for 24 or 
36 months. Here, we should note that the although the strength of the correlations in Fig S9 differ, we 
observe a consensus between the stability-indicating techniques, and they were all useful for 
identifying the two PPI13 formulations that were least stable during long-term storage, i.e. the ones 
based on 10 mM histidine pH 5.0 including arginine salts. Taking a decision which protein formulations 
should (or should not) be selected for further development is easier in such cases due to the general 
agreement between the stability-indicating parameters. 
An interesting observation is that in the long-term stability studies with PPI13 we did not detect 
an increase in the amount of soluble aggregates but found that the protein aggregates by forming 
large particles in the conditions providing lower conformational and colloidal stability. When the protein 
is refolded from 9 M urea using the ReFOLD assay, we observe substantial monomer loss but only a 
small increase in the soluble aggregates, identified as dimers (Fig 5a). For comparison, two other 
IgG1-type monoclonal antibodies, which we studied earlier, form much more soluble aggregates with 
various sizes after refolding from urea20. Based on these results, it is tempting to speculate that the 
aggregation mechanisms of PPI13 during long-term storage and during refolding from urea could be 
similar. 
 
CONCLUSION 
In this work, we applied orthogonal high- and medium-throughput techniques to probe the 
effect of 280 mM sucrose, 140 mM ArgHCl and 70 mM ArgGlu on the stability of a monoclonal 
antibody named PPI13. We found good agreement between various parameters showing that, under 
low ionic strength conditions, sucrose stabilizes the protein, while arginine salts in this concentration 
reduce the colloidal protein stability at both pH 5.0 and pH 6.5. This reduction can be explained by the 
increase in ionic strength and the screening of electrostatic repulsion between the protein monomers, 
once ions from arginine salts bind to the surface of the protein, as evident by our STD-NMR 
experiments. We also performed long-term stability studies to validate the observations from the quick 
biophysical characterization. The two parameters that show the strongest correlation with the long-
term stability data are the temperature of the first thermal unfolding inflection point and the relative 
monomer yield after isothermal refolding from urea. Formulations in which PPI13 unfolds at lower 
temperature and has low colloidal stability are the formulations in which a considerable amount of 
subvisible particles were formed after 12-month storage at 25 °C.   
Our work is important in two aspects. First, it shows that PPI13 formulations where multiple 
biophysical techniques indicate low physical stability are also formulations in which the protein 
aggregates during long-term storage. And second, we show that whether arginine salts will inhibit or 
promote aggregation is highly dependent on other solution parameters, such as the starting ionic 
strength of the solution.  Although arginine can undoubtedly bring benefits in formulations where the 
short-ranged hydrophobic interactions are important (e.g. at high protein concentration, or where long-
range electrostatic repulsions are already largely screened), arginine salts can have a detrimental 
effect on the protein colloidal stability in protein formulations where electrostatic repulsion is important 
for suppressing protein aggregation (e.g. in dilute protein solutions at low ionic strength). 
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FIGURE LEGENDS 
Figure 1. Thermal protein unfolding of PPI13 at different pH (a) and effect of additives on the thermal 
unfolding at pH 5.0 (d) and pH 6.5 (g). Effect of temperature on the apparent hydrodynamic radius Rh 
of PPI13 at different pH (b) and effect of additives on Rh during heating at pH 5.0 (e) and pH 6.5 (h). 
Effect of temperature on the excess scattering of PPI13 formulations at different pH (c) and effect of 
additives on the excess scattering during heating at pH 5.0 (f) and pH 6.5 (i). In A, C, D, F, G,  and I 
the datapoint density is reduced to improve clarity. The concentration of PPI13 is 5 g/L in all samples. 
Figure 2. Concentration dependence of the mutual diffusion coefficient of PPI13 at pH 5.0 (a) and pH 
6.5 (b) in presence of no additive (squares), 280 mM sucrose (circles), 140 mM ArgHCl (triangles up) 
and 70 mM ArgGlu (triangles down). The data is overlay of triplicates. The lines present a linear fit to 
the points. 
Figure 3. Overview of the results obtained with SAXS: P(r) functions of PPI13 at pH 5.0 (a) and pH 6.5 
(b), Dmax at pH 5.0 (c) and pH 6.5 (d), Mm at pH 5.0 (e) and pH 6.5 (f).  
Figure 4. Protein-additive saturation transfer amplification factors (AFSTD) measured for individual 
atoms of various additives added to PPI13 at pH 5.0 (left column) and 6.5 (right column), for sucrose 
(a, b), ArgHCl (c, d) and ArgGlu (e, f). The labels below the graphs specify individual atoms for which 
AFSTD was measured, and the insets show chemical structure of the additive molecules used with 
matching labelling of the atoms. 
Figure 5. (a) SEC chromatogram of native and refolded PPI13 in 10 mM histidine pH 5.0. In a 
separate experiment, the peak at 14.2 minutes was identified as a dimer using SEC coupled to multi-
angle light scattering (data not shown). Relative monomer yield and soluble protein yield of PPI13 
when the protein is refolded from 9 M urea at pH 5.0 (b) and pH 6.5 (c) with no additive, 280 mM 
sucrose, 140 mM ArgHCl or 70 mM ArgGlu. The values in B and C are mean of triplicates, the error 
bar is the standard deviation. 
Figure 6. Effect of additives on the monomer recovery and loss of soluble PPI13 from size exclusion 
chromatography after 12 months of storage. (a) storage at 25 °C at pH 5.0, (b) storage at 25 °C at pH 
6.5, (c) storage at 4 °C at pH 5.0, (d) storage at 4 °C at pH 6.5; 
Figure 7. Effect of pH and additives on the subvisible particles of PPI13 measured during storage for 
12 months at 25 °C 
 
Table 1. Stability-indicating parameters of PPI13 in 10 mM histidine buffer with pH 5.0 and pH 6.5 in 
presence of different additives. The values are mean of triplicates, the error presents the standard 
deviation.  
 Additive 
From nanoDSF® From DLS 
IP1, °C IP2, °C Tagg, °C kD (mL/g) D0  (x10-07 cm2/s) 
pH 5.0 
No 58.20 ±0.05 80.17 ±0.07 78.1 ±0.3 34.2 ±3.8 4.69 ±0.08 
280 mM 
Sucrose 
59.32 ±0.06 81.04 ±0.05 78.9 ±0.1 17.1 ±2.1 4.15 ±0.09 
140 mM ArgHCl 55.43 ±0.06 76.99 ±0.03 60.8 ±0.9 -13.9 ±0.3 4.48 ±0.02 
70 mM ArgGlu 59.70 ±0.09 80.37 ±0.01 73.3 ±0.2 -11.1 ±0.9 4.48 ±0.03 
pH 6.5 
No 64.33 ±0.100 80.11 ±0.04 76.7 ±0.4 27.3 ±1.5 5.01 ±0.03 
280 mM 
Sucrose 
65.86 ±0.11 81.24 ±0.03 77.4 ±0.4 10.7 ±0.8 4.62 ±0.04 
140 mM ArgHCl 62.25 ±0.06 78.97 ±0.04 73.3 ±0.5 -15.7 ±0.7 4.55 ±0.02 
70 mM ArgGlu 63.84 ±0.02 80.36 ±0.01 74.1 ±0.5 -16.6 ±1.8 4.46 ±0.06 
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